Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients
Novo Nordisk said on Monday its next-generation experimental drug, CagriSema, delivered an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes,
September 21, 2026